Serum lipids in epileptic children treated with carbamazepine and valproate.
Serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol, triglyceride, apolipoproteins A1 and B levels were studied in 57 healthy children and in 39 children with epilepsy who had been receiving carbamazepine (CBZ) (23 children) for 1.58 +/- 1.10 years or valproic acid (VPA) (16 children) for 1.34 +/- 1.11 years. In patients receiving CBZ, mean TC level, mean LDL-C level, mean TC/HDL-C ratio and mean LDL-C/HDL-C ratio-were significantly higher than controls. None of the mean levels of serum lipids evaluated in patients receiving VPA was significantly different from the corresponding control group mean. Changes in serum lipids correlated with neither duration of therapy or plasma antiepileptic levels nor age or gender.


CONCLUSIONS
Our results suggested that CBZ, a hepaticenzyme-inducing drug, affects serum lipid status. Long-term prospective studies are necessary to determine whether chronic CBZ therapy is a risk factor for atherosclerotic disorders.
Sözüer
D T
DT
Bakirköy State Hospital for Neurological and Psychiatric Diseases, Department of Neurology, Istanbul, Turkey.
Atakil
D
D
Dogu
O
O
Baybas
S
S
Arpaci
B
B
D000293:Adolescent; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D001053:Apolipoproteins / Q000097:blood; D002220:Carbamazepine / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D014280:Triglycerides / Q000097:blood; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use
D000927:Anticonvulsants; D001053:Apolipoproteins; D008055:Lipids; D014280:Triglycerides; D002220:Carbamazepine; D014635:Valproic Acid; D002784:Cholesterol